Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $44.71, but opened at $48.30. Zealand Pharma A/S shares last traded at $48.30, with a volume of 240 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ZLDPF shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Zealand Pharma A/S has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Trading Up 2.2%

The company has a market cap of $3.16 billion, a PE ratio of 3.25 and a beta of 0.88. The company has a quick ratio of 23.57, a current ratio of 23.57 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $53.07 and its 200-day moving average is $66.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. The company had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $19.69 million. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%. As a group, sell-side analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.